Transmembrane helix-helix interactions involved in ErbB receptor signaling

Cell Adhesion and Migration

Volumn 4, Issue 2, 2010, Pages 299-312

  Cymer, Florian ^a   Schneider, Dirk ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

EGFR; ErbB; Helix helix interaction; Receptor; Receptor tyrosine kinase; Signaling; Transmembrane proteins

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERYTHROPOIETIN RECEPTOR; HELIX LOOP HELIX PROTEIN; HETERODIMER; HOMODIMER; LIGAND; LIPID; MEMBRANE PROTEIN; PERTUZUMAB; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL MEMBRANE; CELL MIGRATION; COMPLEX FORMATION; CYTOPLASM; DEREGULATION; DIMERIZATION; ENDOCYTOSIS; EXTRACELLULAR MATRIX; HUMAN; INTRACELLULAR MEMBRANE; LIGAND BINDING; LIPID MEMBRANE; NEOPLASM; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE;

ANIMALS; CELL MEMBRANE; HUMANS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 77953594623     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.4.2.11191     Document Type: Review

References (142)

1. Sanders CR, Myers JK. Disease-related misassembly of membrane proteins. Annu Rev Biophys Biomol Struct 2004; 33:25-51.
2. Wallin E, von Heijne G. Genome-wide analysis of integral membrane proteins from eubacterial, archaean and eukaryotic organisms. Protein Sci 1998; 7:1029-38.
3. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1:727-30.
4. Alberts B. Molecular biology of the cell. New York: Garland Science 2008.
5. Langosch D, Arkin IT. Interaction and conformational dynamics of membrane-spanning protein helices. Protein Sci 2009; 18:1343-58.
6. Matthews EE, Zoonens M, Engelman DM. Dynamic helix interactions in transmembrane signaling. Cell 2006; 127:447-50.
7. Levchenko A. Dynamical and integrative cell signaling: challenges for the new biology. Biotechnol Bioeng 2003; 84:773-82.
8. von Heijne G. The membrane protein universe: what's out there and why bother? J Intern Med 2007; 261:543-57.
9. Pokutta S, Weis WI. Structure and mechanism of cadherins and catenins in cell-cell contacts. Annu Rev Cell Dev Biol 2007; 23:237-61.
10. Stemmler MP. Cadherins in development and cancer. Mol Biosyst 2008; 4:835-50.
11. Goodwin M, Yap AS. Classical cadherin adhesion molecules: coordinating cell adhesion, signaling and the cytoskeleton. J Mol Histol 2004; 35:839-44.
12. Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 1989; 8:1711-7.
13. Tomschy A, Fauser C, Landwehr R, Engel J. Homophilic adhesion of E-cadherin occurs by a cooperative two-step interaction of N-terminal domains. EMBO J 1996; 15:3507-14.
14. Ozawa M, Kemler R. The membrane-proximal region of the E-cadherin cytoplasmic domain prevents dimerization and negatively regulates adhesion activity. J Cell Biol 1998; 142:1605-13.
15. Brieher WM, Yap AS, Gumbiner BM. Lateral dimerization is required for the homophilic binding activity of C-cadherin. J Cell Biol 1996; 135:487-96.
16. Huber O, Kemler R, Langosch D. Mutations affecting transmembrane segment interactions impair adhesiveness of E-cadherin. J Cell Sci 1999; 112:4415-23.
17. Ozawa M. Lateral dimerization of the E-cadherin extracellular domain is necessary but not sufficient for adhesive activity. J Biol Chem 2002; 277:19600-8.
18. Yonekura S, Ting CY, Neves G, Hung K, Hsu SN, Chiba A, et al. The variable transmembrane domain of Drosophila N-cadherin regulates adhesive activity. Mol Cell Biol 2006; 26:6598-608.
19. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67:39-61.
20. Wilson IA, Jolliffe LK. The structure, organization, activation and plasticity of the erythropoietin receptor. Curr Opin Struct Biol 1999; 9:696-704.
21. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415-21.
22. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998; 395:511-6.
23. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999; 283:987-90.
24. Kubatzky KF, Ruan W, Gurezka R, Cohen J, Ketteler R, Watowich SS, et al. Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Curr Biol 2001; 11:110-5.
25. Zhou FX, Merianos HJ, Brunger AT, Engelman DM. Polar residues drive association of polyleucine transmembrane helices. Proc Natl Acad Sci USA 2001; 98:2250-5.
26. Gratkowski H, Lear JD, DeGrado WF. Polar side chains drive the association of model transmembrane peptides. Proc Natl Acad Sci USA 2001; 98:880-5.
27. Li JP, D'Andrea AD, Lodish HF, Baltimore D. Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature 1990; 343:762-4.
28. Constantinescu SN, Liu X, Beyer W, Fallon A, Shekar S, Henis YI, et al. Activation of the erythropoietin receptor by the gp55-P viral envelope protein is determined by a single amino acid in its transmembrane domain. EMBO J 1999; 18:3334-47.
29. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19:5548-57.
30. Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 2007; 19:117-23.
31. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-37.
32. McKern NM, Lawrence MC, Streltsov VA, Lou MZ, Adams TE, Lovrecz GO, et al. Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature 2006; 443:218-21.
33. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999; 98:641-50.
34. Bennasroune A, Gardin A, Auzan C, Clauser E, Dirrig-Grosch S, Meira M, et al. Inhibition by transmembrane peptides of chimeric insulin receptors. Cell Mol Life Sci 2005; 62:2124-31.
35. Finger C, Escher C, Schneider D. The single transmembrane domains of human receptor tyrosine kinases encode self-interactions. Sci Signal 2009; 2:56.
36. Takahashi K, Yonezawa K, Nishimoto I. Insulin-like Growth Factor I Receptor Activated by a Transmembrane Mutation 1074/jbc.270.32.19041. Journal of Biological Chemistry 1995; 270:19041-5.
37. Cheatham B, Shoelson SE, Yamada K, Goncalves E, Kahn CR. Substitution of the erbB-2 oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin and insulin-receptor substrate 1. Proc Natl Acad Sci USA 1993; 90:7336-40.
38. Flörke RR, Schnaith K, Passlack W, Wichert M, Kuehn L, Fabry M, et al. Hormone-triggered conformational changes within the insulin-receptor ectodomain: requirement for transmembrane anchors. Biochem J 2001; 360:189-98.
39. Yamada K, Goncalves E, Kahn CR, Shoelson SE. Substitution of the insulin receptor transmembrane domain with the c-neu/erbB2 transmembrane domain constitutively activates the insulin receptor kinase in vitro. J Biol Chem 1992; 267:12452-61.
40. Qiu C, Tarrant MK, Boronina T, Longo PA, Kavran JM, Cole RN, et al. In vitro enzymatic characterization of near full length EGFR in activated and inhibited states. Biochemistry 2009; 48:6624-32.
41. Schlessinger J, Lemmon MA. SH2 and PTB domains in tyrosine kinase signaling. Sci STKE 2003; 2003:12.
42. Carpenter G, Cohen S. Human epidermal growth factor: binding of the polypeptide to human fibroblasts and stimulation of cell proliferation. Natl Cancer Inst Monogr 1978:149-56.
43. Hynes NE, Horsch K, Olayioye MA, Badache A. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer 2001; 8:151-9.
44. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110:775-87.
45. Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, et al. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009; 137:1293-307.
46. Bouyain S, Longo PA, Li S, Ferguson KM, Leahy DJ. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci USA 2005; 102:15024-9.
47. Wood ER, Shewchuk LM, Ellis B, Brignola P, Brashear RL, Caferro TR, et al. 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases. Proc Natl Acad Sci USA 2008; 105:2773-8.
48. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756-60.
49. Cho HS, Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002; 297:1330-3.
50. Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 2006; 16:649-56.
51. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 1997; 324:855-61.
52. Moriki T, Maruyama H, Maruyama IN. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J Mol Biol 2001; 311:1011-26.
53. Tao RH, Maruyama IN. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Sci 2008; 121:3207-17.
54. Wehrman TS, Raab WJ, Casipit CL, Doyonnas R, Pomerantz JH, Blau HM. A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc Natl Acad Sci USA 2006; 103:19063-8.
55. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003; 284:54-65.
56. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999; 96:4995-5000.
57. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL, 3rd. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 1994; 91:8132-6.
58. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211-25.
59. Fuller SJ, Sivarajah K, Sugden PH. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol 2008; 44:831-54.
60. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004; 58:903-13.
61. Lemmon MA. Ligand-induced ErbB receptor dimerization. Exp Cell Res 2009; 315:638-48.
62. Lemmon MA, Bu Z, Ladbury JE, Zhou M, Pinchasi D, Lax I, et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J 1997; 16:281-94.
63. Ferguson KM, Darling PJ, Mohan MJ, Macatee TL, Lemmon MA. Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. EMBO J 2000; 19:4632-43.
64. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003; 11:507-17.
65. Dawson JP, Bu Z, Lemmon MA. Ligand-induced structural transitions in ErbB receptor extracellular domains. Structure 2007; 15:942-54.
66. Alvarado D, Klein DE, Lemmon MA. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. Nature 2009; 461:287-91.
67. Gullick WJ. A new model for the interaction of EGF-like ligands with their receptors: the new one-two. Eur J Cancer 1994; 30:2186.
68. Dawson JP, Berger MB, Lin CC, Schlessinger J, Lemmon MA, Ferguson KM. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 2005; 25:7734-42.
69. Sorokin A. Activation of the EGF receptor by insertional mutations in its juxtamembrane regions. Oncogene 1995; 11:1531-40.
70. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, Carpenter G. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 2009; 34:641-51.
71. Thiel KW, Carpenter G. Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proc Natl Acad Sci USA 2007; 104:19238-43.
72. McLaughlin S, Smith SO, Hayman MJ, Murray D. An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family. J Gen Physiol 2005; 126:41-53.
73. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006; 125:1137-49.
74. Chantry A. The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors. J Biol Chem 1995; 270:3068-73.
75. Heisermann GJ, Wiley HS, Walsh BJ, Ingraham HA, Fiol CJ, Gill GN. Mutational removal of the Thr669 and Ser671 phosphorylation sites alters substrate specificity and ligand-induced internalization of the epidermal growth factor receptor. J Biol Chem 1990; 265:12820-7.
76. Burke CL, Lemmon MA, Coren BA, Engelman DM, Stern DF. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. Oncogene 1997; 14:687-96.
77. Yarden Y, Schlessinger J. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry 1987; 26:1434-42.
78. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307:521-7.
79. Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, et al. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 1997; 16:4938-50.
80. Mendrola JM, Berger MB, King MC, Lemmon MA. The single transmembrane domains of ErbB receptors self-associate in cell membranes. J Biol Chem 2002; 277:4704-12.
81. Sharpe S, Barber KR, Grant CW. Evidence of a tendency to self-association of the transmembrane domain of ErbB-2 in fluid phospholipid bilayers. Biochemistry 2002; 41:2341-52.
82. Duneau JP, Vegh AP, Sturgis JN. A dimerization hierarchy in the transmembrane domains of the HER receptor family. Biochemistry 2007; 46:2010-9.
83. Lofts FJ, Hurst HC, Sternberg MJ, Gullick WJ. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene 1993; 8:2813-20.
84. Bennasroune A, Fickova M, Gardin A, Dirrig-Grosch S, Aunis D, Cremel G, Hubert P. Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol Biol Cell 2004; 15:3464-74.
85. Li E, Hristova K. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry 2006; 45:6241-51.
86. Popot JL, Engelman DM. Membrane protein folding and oligomerization: the two-stage model. Biochemistry 1990; 29:4031-7.
87. Engelman DM, Chen Y, Chin C-N, Curran AR, Dixon AM, Dupuy AD, et al. Membrane protein folding: beyond the two stage model. FEBS Lett 2003; 555:122-5.
88. Lemmon MA, Flanagan JM, Treutlein HR, Zhang J, Engelman DM. Sequence specificity in the dimerization of transmembrane alpha-helices. Biochemistry 1992; 31:12719-25.
89. MacKenzie KR, Prestegard JH, Engelman DM. A transmembrane helix dimer: structure and implications. Science 1997; 276:131-3.
90. Brosig B, Langosch D. The dimerization motif of the glycophorin A transmembrane segment in membranes: importance of glycine residues. Protein Sci 1998; 7:1052-6.
91. Senes A, Gerstein M, Engelman DM. Statistical analysis of amino acid patterns in transmembrane helices: the GxxxG motif occurs frequently and in association with beta-branched residues at neighboring positions. J Mol Biol 2000; 296:921-36.
92. Russ WP, Engelman DM. The GxxxG motif: a framework for transmembrane helix-helix association. J Mol Biol 2000; 296:911-9.
93. Kim S, Jeon TJ, Oberai A, Yang D, Schmidt JJ, Bowie JU. Transmembrane glycine zippers: physiological and pathological roles in membrane proteins. Proc Natl Acad Sci USA 2005; 102:14278-83.
94. Schneider D, Engelman DM. Involvement of transmembrane domain interactions in signal transduction by alpha/beta integrins. J Biol Chem 2004; 279:9840-6.
95. Schneider D, Engelman DM. Motifs of two small residues can assist but are not sufficient to mediate transmembrane helix interactions. J Mol Biol 2004; 343:799-804.
96. Unterreitmeier S, Fuchs A, Schaffler T, Heym RG, Frishman D, Langosch D. Phenylalanine promotes interaction of transmembrane domains via GxxxG motifs. J Mol Biol 2007; 374:705-18.
97. Melnyk RA, Kim S, Curran AR, Engelman DM, Bowie JU, Deber CM. The affinity of GXXXG motifs in transmembrane helix-helix interactions is modulated by long-range communication. J Biol Chem 2004; 279:16591-7.
98. Senes A, Engel DE, DeGrado WF. Folding of helical membrane proteins: the role of polar, GxxxG-like and proline motifs. Curr Opin Struct Biol 2004; 14:465-79.
99. Burke CL, Stern DF. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol Cell Biol 1998; 18:5371-9.
100. Bell CA, Tynan JA, Hart KC, Meyer AN, Robertson SC, Donoghue DJ. Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase. Mol Biol Cell 2000; 11:3589-99.
101. Sternberg MJ, Gullick WJ. A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. Protein Eng 1990; 3:245-8.
102. Escher C, Cymer F, Schneider D. Two GxxxG-like motifs facilitate promiscuous interactions of the human ErbB transmembrane domains. J Mol Biol 2009; 389:10-6.
103. Gerber D, Sal-Man N, Shai Y. Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization. J Biol Chem 2004; 279:21177-82.
104. Bocharov EV, Mineev KS, Volynsky PE, Ermolyuk YS, Tkach EN, Sobol AG, et al. Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state. J Biol Chem 2008; 283:6950-6.
105. Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 2002; 99:15937-40.
106. Clayton AH, Walker F, Orchard SG, Henderson C, Fuchs D, Rothacker J, et al. Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. J Biol Chem 2005; 280:30392-9.
107. Khazaie K, Schirrmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 1993; 12:255-74.
108. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004; 44:195-217.
109. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9:1165-72.
110. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28.
111. Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 1988; 8:5570-4.
112. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986; 45:649-57.
113. Smith SO, Smith CS, Bormann BJ. Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor. Nat Struct Biol 1996; 3:252-8.
114. Smith SO, Smith C, Shekar S, Peersen O, Ziliox M, Aimoto S. Transmembrane interactions in the activation of the Neu receptor tyrosine kinase. Biochemistry 2002; 41:9321-32.
115. Cao H, Bangalore L, Dompe C, Bormann BJ, Stern DF. An extra cysteine proximal to the transmembrane domain induces differential cross-linking of p185neu and p185neu. J Biol Chem 1992; 267:20489-92.
116. Beevers AJ, Kukol A. The transmembrane domain of the oncogenic mutant ErbB-2 receptor: a structure obtained from site-specific infrared dichroism and molecular dynamics. J Mol Biol 2006; 361:945-53.
117. Papewalis J, Nikitin A, Rajewsky MF. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 1991; 19:5452.
118. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000; 92:412-7.
119. Miller M, Kennewell A, Takayama Y, Bruskin A, Bishop JM, Johnson G, Symonds G. Transformation of early erythroid precursor cells (BFU-E) by a recombinant murine retrovirus containing v-erb-B. Oncogene 1990; 5:1125-31.
120. Zhu HJ, Iaria J, Orchard S, Walker F, Burgess AW. Epidermal growth factor receptor: association of extracellular domain negatively regulates intracellular kinase activation in the absence of ligand. Growth Factors 2003; 21:15-30.
121. Cymer F, Schneider D. Lessons from viruses: controlling the function of transmembrane proteins by interfering transmembrane helices. Curr Med Chem 2008; 15:779-85.
122. Yin H, Slusky JS, Berger BW, Walters RS, Vilaire G, Litvinov RI, et al. Computational design of peptides that target transmembrane helices. Science 2007; 315:1817-22.
123. Szabo A, Horvath G, Szollosi J, Nagy P. Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements. Biophys J 2008; 95:2086-96.
124. Clayton AH, Tavarnesi ML, Johns TG. Unligated epidermal growth factor receptor forms higher order oligomers within microclusters on A431 cells that are sensitive to tyrosine kinase inhibitor binding. Biochemistry 2007; 46:4589-97.
125. Gan HK, Walker F, Burgess AW, Rigopoulos A, Scott AM, Johns TG. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. J Biol Chem 2007; 282:2840-50.
126. Nagy P, Jenei A, Kirsch AK, Szollosi J, Damjanovich S, Jovin TM. Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy. J Cell Sci 1999; 112:1733-41.
127. Kani K, Warren CM, Kaddis CS, Loo JA, Landgraf R. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin. J Biol Chem 2005; 280:8238-47.
128. Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P, et al. Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA 2005; 102:2760-5.
129. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 1997; 272:30429-38.
130. Ushio-Fukai M, Hilenski L, Santanam N, Becker PL, Ma Y, Griendling KK, Alexander RW. Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. J Biol Chem 2001; 276:48269-75.
131. Ringerike T, Blystad FD, Levy FO, Madshus IH, Stang E. Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. J Cell Sci 2002; 115:1331-40.
132. Keating E, Nohe A, Petersen NO. Studies of distribution, location and dynamic properties of EGFR on the cell surface measured by image correlation spectroscopy. Eur Biophys J 2008; 37:469-81.
133. Waterman H, Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett 2001; 490:142-52.
134. Fantini J, Garmy N, Mahfoud R, Yahi N. Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases. Expert Rev Mol Med 2002; 4:1-22.
135. Hanzal-Bayer MF, Hancock JF. Lipid rafts and membrane traffic. FEBS Lett 2007; 581:2098-104.
136. Webb RJ, East JM, Sharma RP, Lee AG. Hydrophobic mismatch and the incorporation of peptides into lipid bilayers: a possible mechanism for retention in the Golgi. Biochemistry 1998; 37:673-9.
137. Bretscher MS, Munro S. Cholesterol and the Golgi apparatus. Science 1993; 261:1280-1.
138. Nezil FA, Bloom M. Combined influence of cholesterol and synthetic amphiphillic peptides upon bilayer thickness in model membranes. Biophys J 1992; 61:1176-83.
139. Lopez PH, Schnaar RL. Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol 2009.
140. Roepstorff K, Thomsen P, Sandvig K, van Deurs B. Sequestration of epidermal growth factor receptors in non-caveolar lipid rafts inhibits ligand binding. J Biol Chem 2002; 277:18954-60.
141. Sottocornola E, Misasi R, Mattei V, Ciarlo L, Gradini R, Garofalo T, et al. Role of gangliosides in the association of ErbB2 with lipid rafts in mammary epithelial HC11 cells. Febs J 2006; 273:1821-30.
142. Khemtemourian L, Buchoux S, Aussenac F, Dufourc EJ. Dimerization of Neu/Erb2 transmembrane domain is controlled by membrane curvature. Eur Biophys J 2007; 36:107-12.